La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

INmune Bio Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

RJ Tesi

Directeur général

US$1.7m

Rémunération totale

Pourcentage du salaire du PDG	29.5%
Durée du mandat du directeur général	9yrs
Propriété du PDG	7.8%
Durée moyenne d'occupation des postes de direction	9yrs
Durée moyenne du mandat des membres du conseil d'administration	7.8yrs

Mises à jour récentes de la gestion

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

Jul 12

Recent updates

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

Jul 12

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Apr 05

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Mar 25

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

Dec 02

INmune Bio A No-Brainer Investment

Oct 13

INmune Bio: High-Risk High-Reward Alzheimer's Play

Aug 18

Our Bullish Take On INmune Bio's Drug Pipeline

Aug 12

INmune Bio: Underfollowed AD Player With Very Bullish August Momentum

Jul 13

Companies Like INmune Bio (NASDAQ:INMB) Are In A Position To Invest In Growth

Jun 25

INmune enters $15M credit facility to fund purchase of Xencor option

Jun 14

Analyse de la rémunération des PDG

Comment la rémunération de RJ Tesi a-t-elle évolué par rapport aux bénéfices de INmune Bio?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$2m	US$501k	-US$30m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$1m	US$455k	-US$27m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$33m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$3m	US$455k	-US$30m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$300k	US$300k	-US$12m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$1m	US$248k	-US$8m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	US$3m	US$120k	-US$12m

Rémunération vs marché: La rémunération totale de RJ ($USD 1.69M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de RJ a augmenté alors que l'entreprise n'est pas rentable.

PDG

RJ Tesi (68 yo)

9yrs

Titularisation

US$1,694,818

Compensation

Dr. Raymond Joseph Tesi, MD, also known as RJ, serves as Director at Bexion Pharmaceuticals, Inc. Dr. Tesi is the Co-Founder of INmuneBio Inc. and has been its Chief Medical Officer and Chairman and serves...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Raymond Tesi	Co-Founder	9yrs	US$1.69m	7.79% $ 10.2m
David Moss	CFO, Treasurer & Secretary	9yrs	US$1.59m	6.42% $ 8.4m
Mark Lowdell	Chief Scientific Officer & Chief Manufacturing Officer	8.9yrs	US$150.24k	7.65% $ 10.0m
Joshua Schoonover	General Counsel	5.7yrs	pas de données	pas de données

9.0yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Gestion expérimentée: L'équipe de direction de INMB est chevronnée et expérimentée (ancienneté moyenne 8.9 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Raymond Tesi	Co-Founder	9yrs	US$1.69m	7.79% $ 10.2m
Marcia Allen	Independent Director	4.8yrs	US$301.66k	pas de données
Scott Juda	Independent Director	6.5yrs	US$301.66k	0.36% $ 474.0k
James Ganjei	Independent Director	8yrs	US$301.66k	0.090% $ 117.8k
Timothy Schroeder	Independent Director	7.8yrs	US$301.26k	0.42% $ 544.1k

7.8yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de INMB sont considérés comme expérimentés (ancienneté moyenne 7.7 ans).

INmune Bio Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

INmune Bio, Inc., Annual General Meeting, Jul 19, 2024

Independent Director recently bought US$246k worth of stock

Insufficient new directors

CFO, Treasurer & Secretary recently bought US$69k worth of stock

INmune Bio, Inc., Annual General Meeting, Jun 01, 2022

Recent updates

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus EPS estimates upgraded to US$2.26 loss

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™? on Proteins That Regulation Synapse in Alzheimer's Patients

INmune Bio, Inc. to Report Q2, 2024 Results on Aug 01, 2024

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial

INmune Bio, Inc., Annual General Meeting, Jul 19, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.67 loss per share (vs US$1.52 loss in FY 2022)

Consensus EPS estimates fall by 24%

INmune Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $9.70224 million.

Independent Director recently bought US$246k worth of stock

Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 35%, EPS upgraded

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2023 Results on Mar 28, 2024

INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’S Disease Program

New minor risk - Share price stability

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA

Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

Consensus revenue estimates increase by 30%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inmune Bio, Inc. Announces Update Regarding Patent Claims Covering Inb16 Cell Line

INmune Bio, Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease Conference

INmune Bio, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’S Disease

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Consensus revenue estimates increase by 51%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. to Report Q2, 2023 Results on Aug 07, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

INmune Bio, Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. Announces Pre-Clinical Data to Support Pioneering Approach to Treating Duchenne Muscular Dystrophy

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 Expressing HER2+ Breast Cancer

Insufficient new directors

INmune Bio, Inc. Focuses on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Price target decreased to US$14.33

Inmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of Xpro1595 in Mild Alzheimer’S Disease

Consensus revenue estimates increase by 24%

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.55 loss in 3Q 2021)

INmune Bio, Inc. to Report Q3, 2022 Results on Nov 02, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.44 loss in 2Q 2021)

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

CFO, Treasurer & Secretary recently bought US$69k worth of stock

INmune Bio: Possibly The Once In A Lifetime Dip

INmune Bio, Inc. Provides Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

Inmune Bio, Inc. Presents Data Demonstrating Xpro™ Promotes Remyelination in Gray Matter At 3rd European Conference on Neuroinflammation

Price target decreased to US$22.33

INmune Bio, Inc., Annual General Meeting, Jun 01, 2022

INmune Bio, Inc. Announces Dosing of First Patient Enrolled in its Phase 2 Trial Using XPro1595 (XPro™) to Treat Neuroinflammation as Cause of Alzheimer’s Disease

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research Annual Meeting 2022

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit